{"id":"W1919283206","doi":"10.1016/j.jaad.2015.03.049","title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","year":2015,"lang":"en","type":"article","venue":"Journal of the American Academy of Dermatology","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":669,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University; Probity Medical Research","funders":"Ortho-McNeil Pharmaceutical; Janssen Pharmaceuticals; Johnson and Johnson; Janssen Biotech; 3M; Merck Sharp and Dohme; Biogen Idec; Genentech; LEO Pharma; Abbott Laboratories; National Institute for Health and Care Research; Sandoz; Novartis; Celgene; Merck; GlaxoSmithKline; Astellas Pharma US; Galderma; Eli Lilly and Company; Pfizer; Amgen; AbbVie; Society of Daughters of the United States Army; Allergan; Merz Therapeutics","keywords":"Apremilast; Medicine; Psoriasis; Plaque psoriasis; Randomized controlled trial; Dermatology; Phosphodiesterase inhibitor; Phosphodiesterase; Internal medicine; Pharmacology; Clinical trial; Psoriatic arthritis; Enzyme","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003696112,0.001025714,0.002193668,0.0003285792,0.0003306034,0.000756355,0.000555639,0.001270123,0.003816084],"category_scores_gemma":[0.002317092,0.0004619915,0.001403416,0.0003669996,0.0006560154,0.0006535869,0.000274935,0.002295707,0.0005209555],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003841172,"about_ca_system_score_gemma":0.0009287206,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003325066,"about_ca_topic_score_gemma":0.0008288414,"domain_scores_codex":[0.9989214,0.0006895685,0.00007928204,0.000127744,0.0001019297,0.0000800613],"domain_scores_gemma":[0.9987326,0.0003712589,0.0003342418,0.00007246812,0.00007773656,0.0004116526],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9323584,0.01379126,0.002234111,0.00108683,0.00118687,0.00008118721,0.00007729654,0.0003244651,0.007600672,0.00008292186,0.001358607,0.03981732],"study_design_scores_gemma":[0.8974946,0.09584972,0.004891492,0.00003922493,0.0004187515,0.00008656541,0.00001428981,0.0001735481,0.0004975798,0.00005692854,0.0004679896,0.000009363332],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980647,0.0112887,0.0007076762,0.000920249,0.0003169799,0.003280132,0.0008040525,0.0001083898,0.001926916],"genre_scores_gemma":[0.9839965,0.005447375,0.00258158,0.001299535,0.0007334094,0.002953486,0.00125764,0.00001962254,0.001711013],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003816084,"threshold_uncertainty_score":0.01954716,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01953649670246773,"score_gpt":0.3023714075668437,"score_spread":0.282834910864376,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}